you are here:

Thyrocare Technologies Ltd.

BSE: 539871 | NSE: THYROCARE |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE594H01019 | SECTOR: Hospitals & Medical Services

BSE Live

Mar 03, 11:23
908.60 -1.90 (-0.21%)
Volume
AVERAGE VOLUME
5-Day
5,092
10-Day
9,443
30-Day
6,248
615
  • Prev. Close

    910.50

  • Open Price

    925.00

  • Bid Price (Qty.)

    912.10 (22)

  • Offer Price (Qty.)

    913.50 (28)

NSE Live

Mar 03, 11:23
913.00 1.40 (0.15%)
Volume
AVERAGE VOLUME
5-Day
137,084
10-Day
203,227
30-Day
131,037
24,977
  • Prev. Close

    911.60

  • Open Price

    912.65

  • Bid Price (Qty.)

    912.25 (10)

  • Offer Price (Qty.)

    913.00 (19)

ANNOUNCEMENTS ON Thyrocare Techn

  • Feb 22, 2021 12:17 Source: BSE

    Thyrocare Technologies - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Arisaig Asia Consumer Fund Limited, Arisaig Next Generation Master Fund ICAV , Segregated Mandate Account – J.P. Morgan Alternative Asset Management Inc., Segregated Mandate Account – Mercer QIF Fund PLC

  • Feb 20, 2021 12:30 Source: BSE

    Thyrocare Technologies - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are filing herewith the transcript of the Earnings Call held on Thursday, February 04, 2021 at 05.00 P.M. local time, post declaration of the Company's unaudited financial results (Stand-alone and Consolidated) for Quarter / Nine Months ended December 31, 2020. This transcript is also made available at our website. Dr. A. Velumani, Chairman & Managing Director, Mr. Arindam Haldar, CEO, Mr. A. Sundararaju, CFO & Executive Director, Mr. Sachin Salvi, Vice-President- Finance, represented the Company.

  • Feb 13, 2021 12:44 Source: BSE

    Thyrocare Technologies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the representatives of following organizations would be having a con-call with us; i) Mirabilis Investment Trust, at 05.00 P.M. on Monday, February 15, 2021. ii) Arisaig Partners, at 03.00 P.M. on Friday, February 19, 2021. Please note that these are subject to any last minute changes.

  • Feb 05, 2021 14:30 Source: BSE

    Thyrocare Technologies - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gordon Yeo

  • Feb 03, 2021 10:40 Source: BSE

    Thyrocare Technologies - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a conference call for the Indian and overseas analysts is arranged by our management to discuss the Company's financial results for Quarter / Nine Months ended December 31, 2020, on Thursday, February 04, 2021 at 05.00 P.M. local time. Dr. A. Velumani, Chairman & Managing Director, Mr. Arindam Haldar, Chief Executive Officer, Mr. A. Sundararaju, Executive Director & CFO and Mr. Sachin Salvi, Vice-President- Finance, will represent the Company. Dial-in details are given in the copy of enclosed Invite of M/s. Nomura Financial Advisory & Securities (India) Pvt. Ltd., who are organizing the con-call.

  • Feb 01, 2021 18:27 Source: BSE

    Thyrocare Technologies - Announcement under Regulation 30 (LODR)-Investor Presentation

    We are forwarding a copy of Presentation on Quarterly Results of our company for the quarter / nine months ended 31-12-2020. Please note that this is only uploaded in our website, and has not been distributed or advertised in newspapers or otherwise publicised.

  • Jan 30, 2021 20:49 Source: BSE

    Thyrocare Technologies - Results- Unaudited Financial Results (Standalone And Consolidated) For The Quarter / Nine Months Ended 31-12-2020

    This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Nine Month Period ended December 31, 2020. The said unaudited financial results, along with the Limited Review Reports, are attached pursuant to Regulation 33 (3) (a) to (c) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board decided to defer the question of further dividend to the next meeting. With regard to appointment of new auditors, the Board authorized Dr. A. Velumani, Chairman & Managing Director, Mr. A. Sundararaju, Executive Director & CFO and Mr. G.S. Hegde, Independent Director, to take a decision and report to the Committee / Board at the earliest. This is to inform that the meeting commenced at 17.30 hours and ended at 20.25 hours today, the 30th January, 2021.

  • Jan 30, 2021 20:41 Source: BSE

    Thyrocare Technologies - Outcome Of Board Meeting

    This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Nine Month Period ended December 31, 2020. The said unaudited financial results, along with the Limited Review Reports, are attached pursuant to Regulation 33 (3) (a) to (c) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board decided to defer the question of further dividend to the next meeting. With regard to appointment of new auditors, the Board authorized Dr. A. Velumani, Chairman & Managing Director, Mr. A. Sundararaju, Executive Director & CFO and Mr. G.S. Hegde, Independent Director, to take a decision and report to the Committee / Board at the earliest. This is to inform that the meeting commenced at 17.30 hours and ended at 20.25 hours today, the 30th January, 2021.

  • Jan 22, 2021 20:49 Source: BSE

    Thyrocare Technologies - Board Meeting Intimation for To Consider & Approve Unaudited Financial Results For Quarter Ended 31-12-2020, To Consider & Decide On Payment Of Interim Dividend, If Any, And To Consider Appointment Of New Auditors In The Plac

    Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to intimate that a meeting of our Board of Directors of the Company will be held on Saturday, January 30, 2021, to inter alia, consider and approve Unaudited Stand-alone and Consolidated Financial Results of the Company for the quarter / nine months ended December 31, 2020, to consider and decide on payment of 2nd Interim Dividend, if any, for the financial year 2020-21 and to decide on the appointment of new Auditors in the place of present Auditors (whose consecutive term of ten years would come to an end as at the conclusion of ensuing Annual General Meeting), subject to approval of the Members at the general meeting. Intimation of the above meeting of the Board of Directors is also being published in newspapers, as required under Regulation 47 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

  • Jan 19, 2021 13:12 Source: BSE

    Thyrocare Technologies - Shareholding for the Period Ended December 31, 2020

    Thyrocare Technologies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Jan 30, 2021
Remark : Quarterly Results & 2nd Interim Dividend